Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 18/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085619 | 0.92 | CHEK2 (0.53) | CHEK2 | |
| SCHEMBL4092456 | 0.89 | CHEK2 (0.58) | CHEK2 | |
| SCHEMBL4082111 | 0.89 | CHEK2 (0.58) | CHEK2 | |
| SCHEMBL4091953 | 0.88 | CHEK2 (0.57) | CHEK2GFER | |
| SCHEMBL4449954 | 0.88 | CHEK2 (0.52) | CHEK2 | |
| SCHEMBL5732767 | 0.87 | CHEK2 (0.59) | CHEK2 | |
| SCHEMBL4093334 | 0.87 | CHEK2 (0.48) | CHEK2 | |
| SCHEMBL4081418 | 0.86 | CHEK2 (0.48) | CHEK2 | |
| SCHEMBL4081581 | 0.86 | ITGB3 (0.52) | CHEK2 | |
| SCHEMBL4088441 | 0.85 | CHEK2 (0.56) | CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589954-B1 | Indoles, benzimidazoles and benztriazoles which are substituted at the 5 or 6 position with a substituent comprising an aromatic moiety linked through a piperazine ring to said indole, benzimidazole or benztriazole are useful | SCIOS, INC. | 2003-07-08 | — | — | US | claimed |
| US-6340685-B1 | ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-01-22 | — | — | US | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1784224-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2007-05-16 | — | — | EP | disclosed |
| EP-1707205-A2 | PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | disclosed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| CN-1658873-A | New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658834-A | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-24 | — | — | CN | disclosed |
| EP-1534282-A2 | PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1496900-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND P38 KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-19 | — | — | EP | disclosed |
| EP-1494645-A2 | METHOD OF TREATING MUCUS HYPERSECRETION | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-12 | — | — | EP | disclosed |
| US-20040044020-A1 | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | US | disclosed |
| WO-2004004725-A2 | PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | disclosed |
| US-20030225089-A1 | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | disclosed |
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | disclosed |
| WO-2003084539-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND P38 KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003084503-A2 | P38 KINASE INHIBITORS FOR TREATING MUCUS HYPERSECRETION_ | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225089-A1 | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | CHRM3, CHRM2, CHRNB1 | CHEK2 130/4885GFER 4254/4885NPSR1 1555/4885 |
| US-20040044020-A1 | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors | CHRM3, CHRNB1, CHRM2 | CHEK2 149/4885GFER 4253/4885NPSR1 1266/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | CHEK2 566/4885GFER 4526/4885NPSR1 723/4885 |
| US-20070123516-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | CHEK2 1350/4885GFER 3658/4885NPSR1 751/4885 |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | CHEK2 566/4885GFER 4526/4885NPSR1 723/4885 |
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | CHEK2 1350/4885GFER 3658/4885NPSR1 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.